

Dear Bijal,

Having reviewed the ACD for the Treatment of Influenza, I can confirm that GlaxoSmithKline have no comments to make. We consider the ACD to be clear, pragmatic, and fairly reflect the evidence available surrounding the treatment of influenza.

Kind Regards,

